March 18, 2025
June 10, 2011 @ 7:30 am CDT
- This event has passed.
Medical Grand Rounds
Adjunctive Rifampin for Staphylococcus Aureus Infections
At the conclusion, the participant should be able to:
1) IDENTIFY the pharmacokinetics and pharmacodynamics of Rifampin; 2) DESCRIBE the properties that make S. Aureus a pathogen in humans and the rationale for Rifampin as an adjunctive treatment option; 3) OVERVIEW the evidence supporting the use of Rifampin as an adjunct to an antimicrobial regimen in serious S. aureus infections. Questions and answers will allow for audience participation.
1) IDENTIFY the pharmacokinetics and pharmacodynamics of Rifampin; 2) DESCRIBE the properties that make S. Aureus a pathogen in humans and the rationale for Rifampin as an adjunctive treatment option; 3) OVERVIEW the evidence supporting the use of Rifampin as an adjunct to an antimicrobial regimen in serious S. aureus infections. Questions and answers will allow for audience participation.